Annette Hanel
Chemnitz, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?
Journal: Annals of hematology
Published: June 07, 2024
Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma.
Journal: Journal of cancer research and clinical oncology
Published: May 15, 2024
Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years.
Journal: Journal of cancer research and clinical oncology
Published: September 09, 2022
Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.
Journal: Journal of cancer research and clinical oncology
Published: April 15, 2021
Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
Journal: Bone marrow transplantation
Published: October 07, 2016
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Journal: British journal of haematology
Published: November 30, 2015
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 17, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026